Bayer shows strong performance – Acquisition of Monsanto agreed

Group sales increase by 2.3 percent (Fx& portfolio adj. 3.5 percent) to EUR 11,262 million / Pharmaceuticals sustains very good business development / Moderate increase in sales at Consumer Health / Crop Science successful in a persistently difficult market environment / EBITDA before special items up by 6.0 percent to EUR 2,682 million / Net income improves by 18.8 percent to EUR 1,187 million / Core earnings per share increase by 2.4 percent to EUR 1.73 / Forecast for core earnings per share raised / Agreed acquisition of Monsanto creates a global leader in agriculture

Source: Bayer Company News - October 26, 2016 Category: Pharmaceuticals Source Type: news